Integrative molecular analyses define the genomic, transcriptomic, and epigenomic correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer
Research Square (Research Square)(2022)
Abstract
Abstract B7-H3 (CD276) is an immune checkpoint overexpressed in prostate cancer with minimal expression in normal tissues and associated with poor prognosis, making it an excellent therapy target. We interrogated B7-H3 expression and its regulation in metastatic castration-resistant prostate cancer (mCRPC). We found greater expression of B7-H3 transcript relative to other immunotherapy targets (CTLA4, PD-L1/2), including in tumors that lacked expression of prostate-specific membrane antigen (PSMA). Enzalutamide-resistant mCRPC cells demonstrated increased amounts of B7-H3, and this was positively associated with resistance signaling pathways. Using a machine learning algorithm, the gene network of B7-H3 was strongly correlated with androgen receptor (AR) and AR co-factor (HOXB13, FOXA1) networks. In mCRPC samples, the B7-H3 promoter and distal enhancer regions exhibited enhanced transcriptional activity and were directly bound by AR and its co-factors. Altogether, our study characterizes epigenetic mechanisms and molecular profiles of B7-H3-expressing mCRPC tumors, which informs optimal precision approaches for mCRPC patients.
MoreTranslated text
Key words
prostate cancer,integrative molecular analyses,epigenomic correlates,castrate-resistant
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined